<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805272</url>
  </required_header>
  <id_info>
    <org_study_id>P070311</org_study_id>
    <nct_id>NCT00805272</nct_id>
  </id_info>
  <brief_title>Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients</brief_title>
  <acronym>IGRAVIH</acronym>
  <official_title>Medical and Economical Evaluation of New Diagnosis Tests of Mycobacterium Tuberculosis, Specific Immune Responses in HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis is a current infection during HIV infection. After infectious contact, some&#xD;
      patients will develop tuberculosis some will only be infected without symptoms, they have&#xD;
      Latent Tuberculosis Infection (LTBI) which can reactivate later.In order to prevent this&#xD;
      tuberculosis reactivation, LTBI diagnosis screening is preconised in HIV-infected patients.&#xD;
      This diagnosis is made till now by the tuberculin skin test (TST) but this test is not&#xD;
      specific of TB. New blood tests (QFTB-G and T-SPOT.TB) specific po MTB infection are now sold&#xD;
      but have not been evaluated in immunocompromised HIV-infected patients.&#xD;
&#xD;
      The primary endpoint of this study is the evaluation of the theoretic therapeutic impact of&#xD;
      the use of IGRAS for diagnosis of LTBI in HIV-infected patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal outcome:&#xD;
&#xD;
      -Theoretic therapeutic impact evaluation of the use of IGRAS for diagnosis of LTBI in&#xD;
      HIV-infected patients .&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  Medico-economic impact of replacement of TST by IGRAs in LTBI screening in HIV infected&#xD;
           patients.&#xD;
&#xD;
        -  Concordance of IGRAs results with TST&#xD;
&#xD;
        -  Concordance between IGRAs.&#xD;
&#xD;
        -  Concordance between IGRAs in accordance to CD4 number(&lt; 100, 100 à 200, 200 à 300, &gt; à&#xD;
           300/mm3).&#xD;
&#xD;
        -  LTBI prevalence in the study group.&#xD;
&#xD;
        -  Effective consequences of tests results on therapeutic outcome of the patients LTBI&#xD;
           criteria and therapeutic recommendations&#xD;
&#xD;
        -  One or 2 positive IGRAs test: LTBI recommended to be LTBI&#xD;
&#xD;
        -  1 negative IGRAs test and one undetermined : no LTBI&#xD;
&#xD;
        -  2 undetermined:&#xD;
&#xD;
        -  No clinical risk and negative TST: no diagnosis, eventually new test at 3 months or&#xD;
           after HAART onset.&#xD;
&#xD;
        -  Clinical risk or TST&gt; 10mm: LTBI recommended to be treated. Therapeutic outcome&#xD;
           evaluation Effective consequences of IGRA's result on patients outcome at 6 months.&#xD;
&#xD;
      Analyzed criteria:&#xD;
&#xD;
      Therapeutic impact:&#xD;
&#xD;
        -  Patients percentage with different therapeutic outcome based on usual recommendations&#xD;
&#xD;
        -  Medico-economic impact&#xD;
&#xD;
        -  Medico-economic impact of both tests as early and late cost - efficacy&#xD;
&#xD;
        -  Statistics&#xD;
&#xD;
      Primary criteria:&#xD;
&#xD;
        -  Percentage of patients for whom therapeutic would have been changed by IGRAs results&#xD;
           compared to usual diagnosis strategy.&#xD;
&#xD;
      Secondary criteria:&#xD;
&#xD;
        -  Concordance of IGRAs with TST&#xD;
&#xD;
        -  Concordance between both IGRAs.&#xD;
&#xD;
        -  Taille: 1000 patients&#xD;
&#xD;
      Timing:&#xD;
&#xD;
      -inclusions: 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the theoretical therapeutic impact (in terms of CHIMIOPROPHYLAXIE antituberculous theoretically managed) of the tracking of tuberculosis-latent by QTF-TB Gold IT® or T-SPOT.TB among patients HIV.</measure>
    <time_frame>J0</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>HIV</condition>
  <condition>Tuberculosis</condition>
  <condition>Latent Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QTF-TB Gold and T-SPOT TB</intervention_name>
    <description>evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IGRAVIH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        18 yrs old Confirmed HIV infection No HAART Consent signed 6 months follow-up possible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Confirmed TB disease No social right pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BOURGARIT Anne</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de médecine interne hôpital saint louis</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>IGRA</keyword>
  <keyword>diagnosis</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

